For more than a decade, pharmaceutical leaders have treated gross to net as a pricing problem. The focus has been on rebates, PBMs, formulary positioning, and increasingly complex contracting strategies. Entire teams are dedicated to modeling discount structures and negotiating access. Yet despite all of this effort, the gap between list price and net revenue […]
Read more
The pharmaceutical industry is facing a growing challenge that is quietly undermining both patient outcomes and commercial performance. While scientific innovation has accelerated and therapies have become more targeted and sophisticated, patient understanding has not kept pace. The result is what can only be described as a patient confusion crisis. For decades, pharmaceutical strategy has […]
Read more
Last week, the FDA released new draft guidance designed to streamline the development of biosimilar drugs by removing certain testing requirements. The goal is to accelerate competition and make biologic therapies more affordable. At first glance, this may appear to be a purely regulatory update. In reality, it highlights a much larger issue in healthcare. […]
Read more
The patient journey has changed dramatically over the past decade. What was once a relatively simple path, visit the doctor, receive a diagnosis, pick up a prescription, and start treatment, has evolved into a much more complex experience for patients. Today, patients must navigate a series of steps that often include genetic testing, specialist referrals, […]
Read more
Every year, millions of prescriptions are written that patients never start. Some patients never pick up their medication. Others start therapy but stop within weeks. For healthcare systems, pharmaceutical companies, and providers alike, this represents one of the most expensive and preventable failures in modern medicine. In the United States alone, roughly one in four […]
Read more
Today we released a press announcement that addresses something pharma leaders already feel in their forecasts, but rarely quantify directly: Patient dropout is quietly draining $250 billion from the U.S. pharmaceutical market every year. You can read the full announcement here:https://www.prnewswire.com/news-releases/pharma-is-losing-250-billion-to-patient-dropout-heres-how-to-stop-it-302696178.html Not because therapies do not work. Not because innovation has slowed. But because patients […]
Read more
What Happens When You Shut Down a Call Center Without a Plan? Pharmaceutical patient services teams are under immense pressure. Costs are rising. Staffing is unstable. Call center turnover is high. And leadership teams are being asked a difficult question: “Can we afford to keep this call center running?” But there is a far more […]
Read more
Pharmaceutical brands are delivering extraordinary science to market. Yet an increasing percentage of prescribed patients never initiate therapy. Not because the product does not work.Not because physicians are not prescribing it. But because the moment education leaves the physician’s hands, initiation risk skyrockets. The hidden gap between prescription and start From a brand perspective, the […]
Read more
Listen to Episode 1: Pharma’s Direct to Patient Pivot: What to Expect in 2026 here. The pharmaceutical industry is moving faster than patients can keep up. Therapies are becoming more specialized. Disease education is more complex. Access models are shifting Direct to Patient. At the same time, physician time is shrinking and patients are being […]
Read more
Enterprise pharma is moving decisively toward direct-to-patient models. This is not a marketing trend or a side project. It is a structural response to access friction, pricing pressure, and the consumerization of healthcare. Patients are behaving more like consumers, distribution models are shifting, and manufacturers are being pulled closer to the patient experience whether they […]
Read more